Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: Lack of association with clinical outcome

G. Ferrandina, G. Scambia, A. Fagotti, G. D'Agostino, P. Benedetti Panici, A. Carbone, S. Mancuso

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The aim of this study was to analyse the clinical significance of Cathepsin D (Cath D) content as determined by an immunoradiometric assay in a series of primary untreated ovarian cancers from 162 patients. In addition, immunohistochemical analysis of Cath D was also performed on a subset of 86 tumours. Cath D levels were distributed in an asymmetrical way and were skewed towards the lower values (median value 20.8 pmol mg-1 protein, range 2.0-99.0 pmol mg-1 protein). No correlation was found between Cath D levels and clinicopathological parameters. However, the percentage of Cath D positivity was significantly higher in oestrogen receptor-positive (57%) compared with oestrogen receptor-negative (36%) cases (P = 0.01). The percentage of Cath D-positive staining was not significantly different for both epithelial (27%) and stromal components (40%). Immunoradiometrically detected Cath D levels were not different according to Cath D stromal immunostaining (P = 0.18), while higher Cath D levels were measured in Cath D-positive than in Cath D-negative tumour epithelial cells (P = 0.027). Survival analysis was conducted on 161 primary untreated ovarian cancer patients. The 5-year overall survival rate was 57% and 55% in Cath D-positive and Cath D-negative patients respectively (P = 0.69). As far as time to progression was concerned, there was no significant difference in the survival rate of patients with either high or low Cath D content (P = 0.56). Similar results have been obtained in the subset of patients in which Cath D was analysed by immunohistochemistry. In conclusion, Cath D measurement in tumour extracts appears to have a limited usefulness in improving the prognostic characterization of ovarian cancer patients.

Original languageEnglish
Pages (from-to)1645-1652
Number of pages8
JournalBritish Journal of Cancer
Volume78
Issue number12
Publication statusPublished - 1998

Fingerprint

Cathepsin D
Ovarian Neoplasms
Estrogen Receptors
Survival Rate
Immunoradiometric Assay
Neoplasms
Survival Analysis

Keywords

  • Cathepsin D
  • Ovarian cancer prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ferrandina, G., Scambia, G., Fagotti, A., D'Agostino, G., Benedetti Panici, P., Carbone, A., & Mancuso, S. (1998). Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: Lack of association with clinical outcome. British Journal of Cancer, 78(12), 1645-1652.

Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer : Lack of association with clinical outcome. / Ferrandina, G.; Scambia, G.; Fagotti, A.; D'Agostino, G.; Benedetti Panici, P.; Carbone, A.; Mancuso, S.

In: British Journal of Cancer, Vol. 78, No. 12, 1998, p. 1645-1652.

Research output: Contribution to journalArticle

Ferrandina, G, Scambia, G, Fagotti, A, D'Agostino, G, Benedetti Panici, P, Carbone, A & Mancuso, S 1998, 'Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: Lack of association with clinical outcome', British Journal of Cancer, vol. 78, no. 12, pp. 1645-1652.
Ferrandina, G. ; Scambia, G. ; Fagotti, A. ; D'Agostino, G. ; Benedetti Panici, P. ; Carbone, A. ; Mancuso, S. / Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer : Lack of association with clinical outcome. In: British Journal of Cancer. 1998 ; Vol. 78, No. 12. pp. 1645-1652.
@article{d18b5ceda0a740999a72eb3ac5f63fa5,
title = "Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: Lack of association with clinical outcome",
abstract = "The aim of this study was to analyse the clinical significance of Cathepsin D (Cath D) content as determined by an immunoradiometric assay in a series of primary untreated ovarian cancers from 162 patients. In addition, immunohistochemical analysis of Cath D was also performed on a subset of 86 tumours. Cath D levels were distributed in an asymmetrical way and were skewed towards the lower values (median value 20.8 pmol mg-1 protein, range 2.0-99.0 pmol mg-1 protein). No correlation was found between Cath D levels and clinicopathological parameters. However, the percentage of Cath D positivity was significantly higher in oestrogen receptor-positive (57{\%}) compared with oestrogen receptor-negative (36{\%}) cases (P = 0.01). The percentage of Cath D-positive staining was not significantly different for both epithelial (27{\%}) and stromal components (40{\%}). Immunoradiometrically detected Cath D levels were not different according to Cath D stromal immunostaining (P = 0.18), while higher Cath D levels were measured in Cath D-positive than in Cath D-negative tumour epithelial cells (P = 0.027). Survival analysis was conducted on 161 primary untreated ovarian cancer patients. The 5-year overall survival rate was 57{\%} and 55{\%} in Cath D-positive and Cath D-negative patients respectively (P = 0.69). As far as time to progression was concerned, there was no significant difference in the survival rate of patients with either high or low Cath D content (P = 0.56). Similar results have been obtained in the subset of patients in which Cath D was analysed by immunohistochemistry. In conclusion, Cath D measurement in tumour extracts appears to have a limited usefulness in improving the prognostic characterization of ovarian cancer patients.",
keywords = "Cathepsin D, Ovarian cancer prognosis",
author = "G. Ferrandina and G. Scambia and A. Fagotti and G. D'Agostino and {Benedetti Panici}, P. and A. Carbone and S. Mancuso",
year = "1998",
language = "English",
volume = "78",
pages = "1645--1652",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer

T2 - Lack of association with clinical outcome

AU - Ferrandina, G.

AU - Scambia, G.

AU - Fagotti, A.

AU - D'Agostino, G.

AU - Benedetti Panici, P.

AU - Carbone, A.

AU - Mancuso, S.

PY - 1998

Y1 - 1998

N2 - The aim of this study was to analyse the clinical significance of Cathepsin D (Cath D) content as determined by an immunoradiometric assay in a series of primary untreated ovarian cancers from 162 patients. In addition, immunohistochemical analysis of Cath D was also performed on a subset of 86 tumours. Cath D levels were distributed in an asymmetrical way and were skewed towards the lower values (median value 20.8 pmol mg-1 protein, range 2.0-99.0 pmol mg-1 protein). No correlation was found between Cath D levels and clinicopathological parameters. However, the percentage of Cath D positivity was significantly higher in oestrogen receptor-positive (57%) compared with oestrogen receptor-negative (36%) cases (P = 0.01). The percentage of Cath D-positive staining was not significantly different for both epithelial (27%) and stromal components (40%). Immunoradiometrically detected Cath D levels were not different according to Cath D stromal immunostaining (P = 0.18), while higher Cath D levels were measured in Cath D-positive than in Cath D-negative tumour epithelial cells (P = 0.027). Survival analysis was conducted on 161 primary untreated ovarian cancer patients. The 5-year overall survival rate was 57% and 55% in Cath D-positive and Cath D-negative patients respectively (P = 0.69). As far as time to progression was concerned, there was no significant difference in the survival rate of patients with either high or low Cath D content (P = 0.56). Similar results have been obtained in the subset of patients in which Cath D was analysed by immunohistochemistry. In conclusion, Cath D measurement in tumour extracts appears to have a limited usefulness in improving the prognostic characterization of ovarian cancer patients.

AB - The aim of this study was to analyse the clinical significance of Cathepsin D (Cath D) content as determined by an immunoradiometric assay in a series of primary untreated ovarian cancers from 162 patients. In addition, immunohistochemical analysis of Cath D was also performed on a subset of 86 tumours. Cath D levels were distributed in an asymmetrical way and were skewed towards the lower values (median value 20.8 pmol mg-1 protein, range 2.0-99.0 pmol mg-1 protein). No correlation was found between Cath D levels and clinicopathological parameters. However, the percentage of Cath D positivity was significantly higher in oestrogen receptor-positive (57%) compared with oestrogen receptor-negative (36%) cases (P = 0.01). The percentage of Cath D-positive staining was not significantly different for both epithelial (27%) and stromal components (40%). Immunoradiometrically detected Cath D levels were not different according to Cath D stromal immunostaining (P = 0.18), while higher Cath D levels were measured in Cath D-positive than in Cath D-negative tumour epithelial cells (P = 0.027). Survival analysis was conducted on 161 primary untreated ovarian cancer patients. The 5-year overall survival rate was 57% and 55% in Cath D-positive and Cath D-negative patients respectively (P = 0.69). As far as time to progression was concerned, there was no significant difference in the survival rate of patients with either high or low Cath D content (P = 0.56). Similar results have been obtained in the subset of patients in which Cath D was analysed by immunohistochemistry. In conclusion, Cath D measurement in tumour extracts appears to have a limited usefulness in improving the prognostic characterization of ovarian cancer patients.

KW - Cathepsin D

KW - Ovarian cancer prognosis

UR - http://www.scopus.com/inward/record.url?scp=0031769373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031769373&partnerID=8YFLogxK

M3 - Article

C2 - 9862578

AN - SCOPUS:0031769373

VL - 78

SP - 1645

EP - 1652

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -